Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

236/433 Matches for
“alcoholic liver disease”

“alcoholic liver disease” Clear all
  1. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 100

    …The assessment of the degree of liver fibrosis in alcoholic liver disease

    FibroTest Alcohol

  2. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 100

    FibroTest Alcohol

  3. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 100

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  4. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 100

    …of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol…

    FibroTest Other

  5. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 100

    …This may indicate the presence of non-alcoholic liver disease in alcoholics.

    ActiTest AshTest FibroTest NashTest +2

  6. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 99

    FibroTest SteatoTest Metabolic

  7. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 99

    Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…

    FibroTest Alcohol

  8. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 99

    …in patients with chronic alcoholic liver disease. ### Methods A total of 221…

    FibroTest Alcohol

  9. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 99

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  10. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 99

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  11. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 98

    …4 (FIB-4), non-alcoholic fatty liver disease fibrosis score (NFS), body…

    FibroTest Metabolic

  12. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 98

    …of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is invasive…

    FibroTest Metabolic

  13. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 98

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  14. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 98

    …values for use in alcoholic liver disease (ALD). The aims of this…

    FibroTest Alcohol

  15. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 98

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  16. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 97

    …spectroscopy), fatty liver index score, non-alcoholic fatty liver disease fibrosis score…

    FibroTest NashTest Metabolic

  17. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 97

    …In patients with alcoholic liver disease, FibrometerA and Hepascore did not improve…

    ActiTest AshTest FibroTest Alcohol

  18. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 97

    …fibrosis in patients with alcoholic liver disease recruited from primary and secondary…

    FibroTest Alcohol

  19. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 97

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  20. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 96

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  21. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 96

    …assess liver fibrosis is insufficiently validated in alcoholic liver disease (ALD). We…

    FibroTest Alcohol

  22. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 96

    alcoholic steato-hepatitis (ASH), in patients with chronic alcoholic liver disease. ### Methods…

    AshTest Alcohol

  23. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 96

    …The best marker of liver fibrosis in alcoholic patients seems to be…

    FibroTest Alcohol

  24. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 96

    …consecutive patients, 97 with alcoholic liver disease (ALD), and 223 non-ALD…

    FibroTest SteatoTest Alcohol

  25. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 95

    …Given that early identification of non-alcoholic fatty liver disease (NAFLD) is…

    NashTest SteatoTest Metabolic

  26. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 95

    …diagnosis of severe alcoholic steatohepatitis (ASH) can require liver biopsy if a…

    AshTest Alcohol

  27. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 95

    …developing complications of end-stage liver disease. Although it lacks sensitivity, ultrasonography…

    ActiTest FibroTest NashTest SteatoTest +1

  28. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 95

    …of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar…

    FibroTest Alcohol HBV HCV +1

  29. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 95

    liver disease, hepatitis C, hepatitis B, and alcoholic or non alcoholic fatty…

    FibroTest Alcohol HBV HCV +3

  30. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 94

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  31. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 94

    …B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were…

    SteatoTest Alcohol HBV HCV +1

  32. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 94

    …Fibrotest in patients with alcoholic liver disease and to compare their diagnostic…

    FibroTest Alcohol

  33. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 94

    liver fibrosis is a vital need for successful individualized management of disease

    FibroTest Alcohol HBV HCV +3

  34. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 94

    …assess liver fibrosis in alcoholic patients. Instant screening of liver fibrosis in…

    FibroTest Alcohol

  35. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 93

    FibroTest Metabolic

  36. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 93

    FibroTest Metabolic

  37. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 93

    …high risk of nonalcoholic fatty liver disease. Noninvasive tests of steatosis, nonalcoholic…

    FibroTest NashTest SteatoTest HIV

  38. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 93

    liver disease, hepatitis C, hepatitis B, alcoholic or nonalcoholic fatty liver disease

    ActiTest FibroTest SteatoTest Alcohol +5

  39. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 92

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  40. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 92

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  41. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 92

    …CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD…

    FibroTest Alcohol HBV HCV +2

  42. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 92

    …one hand and non-alcoholic fatty liver disease (NAFLD) on the other…

    ActiTest FibroTest NashTest SteatoTest +1

  43. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 92

    …of liver morbidity and mortality in non-alcoholic fatty liver disease (NAFLD…

    FibroTest Metabolic

  44. Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    Thabut D et al. · Aliment Pharmacol Ther · 2007 Match 91

    …of PHT in patients with liver disease, and to determine if the…

    FibroTest Alcohol HBV HCV +2

  45. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 91

    …risk factor for non-alcoholic fatty liver disease (NAFLD) occurrence and progression…

    NashTest SteatoTest Metabolic

  46. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 91

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  47. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 91

    …standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The…

    FibroTest Metabolic

  48. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 91

    …virus, nonalcoholic fatty liver disease, alcoholic liver disease, or cholestatic diseases. The…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  49. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 90

    ActiTest AshTest FibroTest NashTest +6

  50. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 90

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  51. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 90

    FibroTest Alcohol HBV HCV +3

  52. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 90

    …chronic liver disease (CLD) such as autoimmune hepatitis, alcoholic liver disease and…

    ActiTest FibroTest Alcohol HBV +3

  53. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 89

    …histologic lesions of non-alcoholic fatty liver disease (NAFLD). The aim was…

    NashTest Metabolic

  54. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 89

    …Fatty liver was diagnosed with abdominal ultrasound and liver steatosis was quantified…

    FibroTest SteatoTest Metabolic

  55. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 89

    …CHB and its consequences on liver injury compared with CHC and NAFLD…

    FibroTest SteatoTest HBV HCV +1

  56. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 89

    liver disease (59.6%) and chronic hepatitis B (52.9%). Liver biopsy…

    FibroTest Alcohol HBV HCV +3

  57. A novel panel of blood markers to assess the degree of liver fibrosis.

    Calès P et al. · Hepatology · 2005 Match 89

    …parameters in viral and alcoholic chronic liver diseases. Measurements included 51 blood…

    FibroTest Alcohol HBV HCV

  58. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 88

    …characterize patients with nonalcoholic fatty liver disease (NAFLD). A multicenter study was…

    ActiTest FibroTest NashTest SteatoTest +1

  59. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 88

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  60. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 88

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  61. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 88

    …standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions in…

    ActiTest FibroTest NashTest SteatoTest +1

  62. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 88

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  63. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 87

    …In multivariate analysis, the predictive variables for advanced liver fibrosis were age…

    FibroTest Metabolic

  64. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 87

    …chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty…

    FibroTest Alcohol HBV HCV +1

  65. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 87

    …the prediction of non-alcoholic liver disease by non-invasive blood tests…

    FibroTest NashTest-2 SteatoTest Metabolic

  66. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 87

    …development of alcohol-related liver disease (ALD). Liver biopsy may be used…

    FibroTest Alcohol

  67. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 87

    FibroTest Metabolic

  68. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 86

    …and quantification in nonalcoholic fatty liver disease (NAFLD). ### Methods Cross-sectional study…

    SteatoTest Metabolic

  69. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 86

    …contributing factor for nonalcoholic fatty liver disease (NAFLD). NAFLD severity and its…

    FibroTest NashTest SteatoTest Metabolic

  70. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 86

    …ELF, ≥10.43; Nonalcoholic Fatty Liver Disease Fibrosis Score, ≥1.80; Fibrotest…

    FibroTest Metabolic

  71. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 86

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  72. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 85

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  73. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 85

    ActiTest FibroTest NashTest-2 Metabolic

  74. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 85

    …of non-invasive biomarkers in liver fibrosis. A scoring system has been…

    ActiTest FibroTest SteatoTest Alcohol +5

  75. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 85

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  76. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 85

    liver disease with liver biopsy, blood fibrosis tests (Nonalcoholic Fatty Liver Disease

    FibroTest Metabolic

  77. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 84

    liver injury are less well validated in non-alcoholic fatty liver disease

    ActiTest FibroTest SteatoTest Metabolic

  78. Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.

    Istaces N et al. · Clin Biochem · 2015 Match 84

    …F3 liver fibrosis stages in non-alcoholic fatty liver disease with 34…

    FibroTest HBV HCV

  79. A simple biological index for detection of alcoholic liver disease in drinkers.

    Poynard T et al. · Gastroenterology · 1991 Match 84

    liver disease (prothrombin time), a sensitive test of alcoholic liver disease (serum…

    Alcohol

  80. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 84

    …patients with chronic liver disease or normal liver tissue that surrounded tumors…

    FibroTest Alcohol HBV HCV +3

  81. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Match 84

    …nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However…

    FibroTest NashTest-2 Metabolic

  82. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 83

    alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver disease

    FibroTest Alcohol HBV HCV +1

  83. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 83

    …We reviewed the landmark studies in metabolic liver disease, sources of the…

    ActiTest FibroTest NashTest NashTest-2 +3

  84. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 83

    …fibrosis were both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66…

    FibroTest Alcohol HBV HCV +3

  85. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 83

    FibroTest Metabolic

  86. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008 Match 82

    FibroTest Alcohol HBV HCV +1

  87. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

    Rinella ME et al. · J Hepatol · 2022 Match 82

    …Non-alcoholic steatohepatitis (NASH) is a chronic, progressive liver disease that can…

    FibroTest Metabolic

  88. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 82

    …Patients with other risk factors for liver disease should be closely monitored…

    FibroTest Other

  89. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 82

    …fibrosis in patients with chronic liver disease. This paper aims to assess…

    FibroTest Alcohol HBV HCV +3

  90. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 82

    …fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer. We…

    FibroTest SteatoTest Metabolic

  91. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 81

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  92. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 81

    liver disease (MASLD) are linked to the development of peripheral artery disease

    ActiTest FibroTest NashTest SteatoTest +1

  93. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Match 81

    …and alcoholic liver disease, with a high correlation between the liver biopsy…

    ActiTest FibroTest Alcohol HBV +1

  94. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 81

    …Further studies are needed to guide strategies for surveillance of liver disease

    FibroTest

  95. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 81

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver

    FibroTest HCV

  96. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 80

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease

    FibroTest Metabolic

  97. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 80

    …standard for assessing nonalcoholic fatty liver disease (NAFLD) histologic lesions in patients…

    FibroTest NashTest SteatoTest Metabolic

  98. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.

    Ivancovsky-Wajcman D et al. · Dig Liver Dis · 2019 Match 80

    …protective potential in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), there…

    FibroTest NashTest SteatoTest Metabolic

  99. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 80

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  100. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

    Bril F et al. · J Investig Med · 2019 Match 80

    …the disease in those patients with non-alcoholic fatty liver disease (NAFLD…

    ActiTest FibroTest NashTest SteatoTest +1

  101. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 79

    …various aspects of liver fibrosis relevant to disease patterns and clinical practice…

    FibroTest SteatoTest HBV HCV +1

  102. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 79

    ActiTest FibroTest Alcohol HBV +3

  103. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 79

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  104. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 79

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  105. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 78

    …for the diagnostic of metabolic liver disease in patients with type-2…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  106. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 78

    liver fibrosis. ### Material And Methods 68 children with chronic liver disease requiring…

    FibroTest

  107. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 78

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  108. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Match 78

    FibroTest Alcohol HBV HCV +1

  109. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 78

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  110. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 77

    …is the prediction of metabolic liver disease (MLD) by noninvasive tests (NITs…

    FibroTest NashTest SteatoTest Metabolic

  111. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 77

    …tests in patients with metabolic liver disease (MASLD). An unmet need is…

    FibroTest-T2D Metabolic

  112. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 77

    Liver biopsy, because of its limitations and risks, might be considered an…

    ActiTest FibroTest HCV

  113. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 77

    …elderly patients without liver disease (group A, 85.2+/-7.3 years…

    FibroTest

  114. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 77

    …Conclusions In patients with chronic liver disease the LCR1 and LCR2 tests…

    FibroTest LCR1 LCR2 Alcohol +3

  115. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 76

    …the early spread of coronavirus disease 2019 (Covid-19) in the general…

    FibroTest COVID

  116. Noninvasive assessment of portal hypertension in patients with cirrhosis.

    Thabut D et al. · Hepatology · 2011 Match 76

    Severe portal hypertension is responsible for complications and death. Although measurement of…

    FibroTest Alcohol HBV HCV +3

  117. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 76

    liver disease. ### Patients And Methods Consecutive patients with chronic liver disease had…

    SteatoTest Metabolic

  118. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.

    Golabi P et al. · Expert Rev Gastroenterol Hepatol · 2016 Match 76

    Nonalcoholic steatohepatitis (NASH) can lead to complications such as liver failure, cirrhosis…

    FibroTest Metabolic

  119. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016 Match 75

    liver-related prognosis in patients with non-alcoholic fatty liver disease (NAFLD…

    FibroTest Metabolic

  120. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 75

    …These consisted of 29 healthy volunteers and 35 patients with chronic liver

    ActiTest FibroTest Alcohol HBV +3

  121. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 75

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  122. The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.

    Gruszewska E et al. · Clin Lab · 2015 Match 75

    …Co-occurrence of alcoholic steatohepatitis and non-alcoholic steatohepatitis in alcoholic patients…

    AshTest NashTest Alcohol

  123. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 75

    …in order to avoid the liver biopsy currently used for selection of…

    FibroTest HCV

  124. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.

    Codjia T et al. · Obes Surg · 2021 Match 74

    …therapeutic options for non-alcoholic fatty liver disease (NAFLD), affecting 90% of…

    FibroTest NashTest SteatoTest Metabolic

  125. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 74

    Liver disease was caused by viral hepatitis (n = 136), alcoholic or nonalcoholic…

    FibroTest Alcohol HBV HCV +2

  126. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 74

    …UK Biobank with apparently healthy liver participants (middle-aged, n=138,125…

    FibroTest

  127. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.

    Ducancelle A et al. · J Clin Gastroenterol · 2017 Match 74

    …225, and alcoholic liver disease (ALD): 265. Sixteen tests [13 blood tests…

    FibroTest Alcohol HBV HCV +2

  128. Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.

    Elkrief L et al. · J Hepatol · 2023 Match 74

    …stage liver disease (MELD) and FibroTest scores, to predict liver-related events…

    FibroTest Alcohol

  129. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 73

    …evaluated for the assessment of liver fibrosis predominantly in patients with viral…

    FibroTest SteatoTest Other

  130. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 73

    …The impact of treatment with ADV vs placebo was assessed on liver

    ActiTest FibroTest HBV

  131. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Review

    Kovalic AJ et al. · Eur J Gastroenterol Hepatol · 2023 Match 73

    liver disease (NAFLD). Due to well-documented flaws associated with liver biopsy…

    FibroTest Metabolic

  132. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 73

    ### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease

    SteatoTest Metabolic

  133. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Match 73

    ### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…

    FibroTest HBV HCV

  134. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 72

    …All patients in the cohort except 1 were managed without a liver

    FibroTest NashTest

  135. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 72

    …patients with chronic liver disease, who received a liver biopsy, transient elastography…

    FibroTest HBV HCV Other

  136. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 72

    …silybum marianum on non alcoholic fatty liver disease (NAFLD). ### Methods In 72…

    SteatoTest Metabolic

  137. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.

    Canivet CM et al. · Hepatology · 2023 Match 72

    …this algorithm in nonalcoholic fatty liver disease (NAFLD). ### Approach And Results One…

    FibroTest Metabolic

  138. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 71

    FibroTest HCV

  139. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 71

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  140. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 71

    …Conclusions In patients with chronic liver disease the LCR1 and LCR2 tests…

    LCR1 LCR2 Alcohol HBV +4

  141. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 71

    …influenced by aetiology of chronic liver disease (CLD) and the stages of…

    FibroTest HBV HCV HIV +1

  142. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 71

    …Investigations included assessment of abdominal ultrasonography, liver biopsy, calculation of body mass…

    HCV

  143. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 70

    …Steatosis was demonstrated in all 5 patients who received liver biopsies during…

    FibroTest Other

  144. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 70

    …Children present severe fatty liver disease with early cirrhosis. Before enzyme replacement…

    FibroTest Metabolic

  145. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 70

    FibroTest Alcohol HBV HCV +1

  146. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 70

    …serum-based assessment of liver fibrosis is still an important diagnostic challenge…

    ActiTest FibroTest HCV

  147. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 70

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  148. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 69

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  149. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 69

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  150. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 69

    …between heart disease and metabolic-dysfunction-associated steatotic liver disease (MASLD); however…

    FibroTest Metabolic

  151. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 69

    liver disease severity. ### Objective To compare the awareness of liver disease severity…

    ActiTest FibroTest Alcohol HBV +3

  152. Non-invasive diagnosis and follow-up of portal hypertension.

    Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022 Match 69

    Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis…

    FibroTest Alcohol HBV HCV +1

  153. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 68

    disease from initial to end stage (mild fibrosis to cirrhosis). Although, liver

    FibroTest HCV

  154. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Match 68

    ### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…

    ActiTest FibroTest HBV

  155. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 68

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  156. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 68

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver

    FibroTest Other

  157. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 67

    …All patients had a liver biopsy. The Hepascore and FibroTest were calculated…

    FibroTest Other

  158. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.

    Naveau S et al. · Dig Dis Sci · 1994 Match 67

    …525 alcoholic patients with different histological stages of alcoholic liver disease to…

    Alcohol

  159. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.

    Thabut D et al. · Liver Int · 2006 Match 67

    …As portal hypertension is related to liver fibrosis, this study aimed to…

    FibroTest Alcohol HBV HCV

  160. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 67

    …depending on etiology and disease stage. Liver biopsy, traditionally regarded as the…

    FibroTest HCV

  161. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 67

    …SVR benefits are well-recognized with reductions in rates of liver complications…

    FibroTest HCV

  162. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 66

    …and ninety patients with chronic liver disease of miscellaneous causes were included…

    FibroTest Alcohol HBV HCV +2

  163. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012 Match 66

    …54 ± 11 years) with chronic liver disease and established cirrhosis were included…

    FibroTest Alcohol HBV HCV +3

  164. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 66

    FibroTest Other

  165. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 66

    …enrolled 103 patients for whom liver biopsy, hepatic elastography results, and laboratory…

    ActiTest FibroTest AIH

  166. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.

    Rossi E et al. · Clin Chem · 2003 Match 66

    ### Background Determining the stage of fibrosis by liver biopsy is important in…

    FibroTest HCV

  167. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 65

    …Therefore, we aimed to study the course of liver disease after an…

    FibroTest HCV HIV

  168. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 65

    …these findings in women and in people with other chronic liver diseases.

    FibroTest HCV

  169. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.

    Halfon P et al. · Comp Hepatol · 2002 Match 65

    …hepatitis C or severe alcoholic liver disease were prospectively recorded and analyzed…

    ActiTest FibroTest Alcohol HCV

  170. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 65

    …including hepatic necroinflammatory activity, on liver stiffness measurement (LSM). This prospective study…

    FibroTest HCV

  171. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 64

    Liver disease in UCDs may be associated with hepatic inflammation, hepatic fibrosis…

    ActiTest FibroTest Other

  172. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 64

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  173. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 64

    ### Background Liver stiffness and non-invasive tests predict overall survival in chronic…

    FibroTest HBV

  174. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 64

    FibroTest Other

  175. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Match 64

    …markers for the diagnosis of liver fibrosis in patients with chronic hepatitis…

    FibroTest HBV

  176. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 63

    …compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography…

    FibroTest Alcohol HBV HCV +3

  177. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 63

    ActiTest AshTest FibroTest NashTest +7

  178. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.

    Chládek J et al. · J Eur Acad Dermatol Venereol · 2013 Match 63

    …However, its use is hampered by the risk of liver fibrosis. ### Aim…

    FibroTest Other

  179. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Match 63

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…

    Metabolic

  180. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 63

    …confirmed by Fibromax testing (or liver biopsy/Fibroscan). Efficacy was assessed by…

    FibroTest HCV

  181. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 62

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  182. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 62

    …FibroSure; LabCorp, Burlington, USA) and liver stiffness measurement (LSM) by Fibroscan (Echosens…

    FibroTest HBV

  183. Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 62

    FibroTest HBV

  184. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.

    Mallet V et al. · Aliment Pharmacol Ther · 2009 Match 62

    …of the liver biopsy (up to 0.94 for liver biopsies >or…

    FibroTest HBV

  185. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 62

    …The reliance on invasive liver biopsy to stage disease is diminishing with…

    FibroTest HBV

  186. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 61

    …We also examined the inter-observer variations after independent review of liver

    FibroTest HCV

  187. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 61

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  188. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 61

    …To evaluate the association between anthropometric measurements and advanced liver disease in…

    ActiTest FibroTest HCV

  189. [The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].

    Supronowicz Ł et al. · Pol Merkur Lekarski · 2013 Match 61

    ### Unlabelled The diagnosis of alcoholic liver disease, steatosis, fibrosis and alcoholic steatohepatitis…

    AshTest FibroTest SteatoTest Alcohol

  190. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication

    Imbert-Bismut F et al. · Lancet · 2001 Match 60

    ### Background Liver biopsy is thought mandatory for management of patients with hepatitis…

    FibroTest HCV

  191. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 60

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  192. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 60

    …chronic liver diseases and whether those levels correlate with disease severity. We…

    FibroTest HCV

  193. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 60

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver

    FibroTest Alcohol HBV HCV +1

  194. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 60

    …evaluation of liver fibrosis in patients with Crohn's disease. ### Methods A…

    FibroTest Other

  195. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 59

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  196. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.

    de Lédinghen V et al. · J Pediatr Gastroenterol Nutr · 2007 Match 59

    …The usefulness of FibroScan in children with chronic liver diseases is unknown…

    FibroTest HBV HCV Other

  197. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.

    Bosselut N et al. · Clin Chim Acta · 2013 Match 59

    ### Background Noninvasive methods for liver fibrosis evaluation in chronic liver diseases have…

    FibroTest HCV

  198. Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.

    Kucharska M et al. · Adv Clin Exp Med · 2015 Match 59

    …the infection, have developed advanced liver disease. Until recently, in order to…

    FibroTest HCV

  199. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 59

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  200. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

    Terrier B et al. · J Hepatol · 2011 Match 58

    …Serum levels of 25(OH)D3 were also significantly correlated with liver

    ActiTest FibroTest HCV HIV

  201. [The prevalence of liver and gallbladder pathologies in overweight and obese patients].

    Popova IR et al. · Klin Med (Mosk) · 2012 Match 58

    …Nonalcoholic fatty liver disease was diagnosed using hepatic elastography and senrum markers…

    ActiTest FibroTest NashTest SteatoTest +1

  202. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.

    Goldschmidt I et al. · J Pediatr Gastroenterol Nutr · 2014 Match 58

    …a late complication of chronic liver disease (LD) in children. The diagnosis…

    FibroTest Other

  203. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023 Match 58

    FibroTest Metabolic

  204. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 57

    …male gender, older age, and NAFLD as a cause of liver disease

    FibroTest Alcohol HBV HCV +3

  205. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 57

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  206. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 57

    …with chronic liver disease and either histological assessment of liver fibrosis (n…

    FibroTest Alcohol HBV HCV +2

  207. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 57

    …of liver affection, and analyse the influence of the HIV disease severity…

    FibroTest HIV

  208. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.

    Fierbinteanu-Braticevici C et al. · World J Gastroenterol · 2009 Match 57

    …Histopathological staging of liver fibrosis according to the METAVIR scoring system served…

    FibroTest HCV

  209. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007 Match 56

    …the entire liver and one taking into account the prevalence of each…

    FibroTest HCV

  210. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 56

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  211. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 56

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  212. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Match 56

    …with advanced liver fibrosis or with steatohepatitis (non-alcoholic steatohepatitis, NASH). ### Aims…

    FibroTest NashTest SteatoTest Metabolic

  213. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 56

    FibroTest HBV

  214. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 55

    …infection or non-HCV-related liver diseases. ### Methods And Results The optimal…

    FibroTest Alcohol HBV HCV +2

  215. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 55

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  216. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 55

    Liver biopsy is the reference standard for assessment of liver fibrosis. However…

    FibroTest HBV

  217. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Match 55

    ### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…

    FibroTest HBV HCV

  218. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 55

    …better biomarkers of drug-induced-liver-injury (DILI). ### Aims We aimed to…

    ActiTest FibroTest Other

  219. Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B.

    Cheng J et al. · PLoS One · 2015 Match 54

    …However, the sensitivity, specificity and diagnostic accuracy in evaluating liver fibrosis of…

    FibroTest HBV

  220. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

    Boursier J et al. · Aliment Pharmacol Ther · 2014 Match 54

    …Significant liver-related events (SLRE) and liver-related deaths were recorded during…

    FibroTest HCV

  221. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.

    Calès P et al. · J Hepatol · 2010 Match 54

    …With reliable diagnosis intervals, liver biopsy can therefore be avoided in all…

    FibroTest HCV HIV

  222. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

    Imbert-Bismut F et al. · Clin Chem Lab Med · 2004 Match 54

    …being developed as alternatives to liver biopsy in patients with chronic hepatitis…

    ActiTest FibroTest HCV

  223. [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

    Piton A et al. · Ann Biol Clin (Paris) · 2005 Match 53

    ### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…

    ActiTest FibroTest

  224. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 53

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  225. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 53

    ActiTest FibroTest HCV

  226. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 53

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  227. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 53

    ActiTest FibroTest HCV

  228. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 52

    …Based on these results, the use of the biochemical markers of liver

    ActiTest FibroTest HCV

  229. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 52

    ActiTest FibroTest HBV

  230. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 52

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  231. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.

    Rosenthal-Allieri MA et al. · Gastroenterol Clin Biol · 2007 Match 52

    …Such discordance is of little clinical consequence for liver fibrosis evaluation in…

    ActiTest FibroTest HCV

  232. A reference material for traceability of aspartate aminotransferase (AST) results.

    Férard G et al. · Clin Chem Lab Med · 2005 Match 52

    Standardization of aspartate aminotransferase (AST) determination is highly desirable for inter-laboratory…

    HBV HCV

  233. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 51

    FibroTest HCV

  234. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.

    Boursier J et al. · BMC Gastroenterol · 2011 Match 51

    …thoroughly evaluated in comparison to liver biopsy, especially in clinical practice and…

    FibroTest HCV

  235. Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

    Calès P et al. · Clin Biochem · 2010 Match 51

    …included 1056 HCV patients with liver biopsy and blood markers. Validation populations…

    FibroTest HCV

  236. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.